Published in PLoS One on February 20, 2014
Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways. Sci Rep (2014) 0.85
25(OH)D Is Effective to Repress Human Cholangiocarcinoma Cell Growth through the Conversion of 25(OH)D to 1α,25(OH)₂D₃. Int J Mol Sci (2016) 0.75
MART-10 represses cholangiocarcinoma cell growth and high vitamin D receptor expression indicates better prognosis for cholangiocarcinoma. Sci Rep (2017) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am (2001) 5.39
Baseline prostate-specific antigen testing at a young age. Eur Urol (2011) 2.95
A novel early growth response gene rapidly induced by fibroblast, epithelial cell and lymphocyte mitogens. Oncogene Res (1988) 2.39
Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet (1996) 2.26
Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol (2002) 2.01
The gene PC3(TIS21/BTG2), prototype member of the PC3/BTG/TOB family: regulator in control of cell growth, differentiation, and DNA repair? J Cell Physiol (2001) 1.80
NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol (2002) 1.55
Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr Rev (2010) 1.54
Structure and expression of TIS21, a primary response gene induced by growth factors and tumor promoters. J Biol Chem (1991) 1.39
Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem (2004) 1.32
Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res (2008) 1.22
TIS21 (/BTG2/PC3) as a link between ageing and cancer: cell cycle regulator and endogenous cell death molecule. J Cancer Res Clin Oncol (2006) 1.15
Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res (1999) 1.13
Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response. Clin Cancer Res (2005) 1.13
BTG gene expression in the p53-dependent and -independent cellular response to DNA damage. Mol Carcinog (2000) 1.12
Antiproliferative proteins of the BTG/Tob family are degraded by the ubiquitin-proteasome system. Eur J Biochem (2002) 1.08
Role of polyamines in p53-dependent apoptosis of intestinal epithelial cells. Cell Signal (2008) 1.07
L-Mimosine blocks cell proliferation via upregulation of B-cell translocation gene 2 and N-myc downstream regulated gene 1 in prostate carcinoma cells. Am J Physiol Cell Physiol (2011) 1.00
Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation. Horm Cancer (2012) 1.00
TIS21/BTG2/PC3 is expressed through PKC-delta pathway and inhibits binding of cyclin B1-Cdc2 and its activity, independent of p53 expression. Exp Cell Res (2004) 0.94
The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. Gene (2002) 0.93
Metallothionein 3: an androgen-upregulated gene enhances cell invasion and tumorigenesis of prostate carcinoma cells. Prostate (2013) 0.91
Prostate-specific antigen kinetics in localized and advanced prostate cancer. BJU Int (2009) 0.90
Impact of BTG2 expression on proliferation and invasion of gastric cancer cells in vitro. Mol Biol Rep (2009) 0.89
Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2. Prostate (2008) 0.89
Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells. Int J Cancer (2011) 0.87
Multimodality therapy for patients with high-risk prostate cancer: current status and future directions. Semin Oncol (2013) 0.87
p53 downregulates the gene expression of mitochondrial aconitase in human prostate carcinoma cells. Prostate (2011) 0.84
The intercalation of DNA double helices with doxorubicin and nogalamycin. J Mol Graph Model (2006) 0.84
Hypoxia upregulates the gene expression of mitochondrial aconitase in prostate carcinoma cells. J Mol Endocrinol (2013) 0.84
Identifying the combination of the transcriptional regulatory sequences on prostate specific antigen and human glandular kallikrein genes. J Urol (2004) 0.83
Mechanisms by which interleukin-6 regulates prostate-specific antigen gene expression in prostate LNCaP carcinoma cells. J Androl (2010) 0.82
Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line. Anticancer Res (2008) 0.82
Down-regulation of the prostate specific antigen promoter by p53 in human prostate cancer cells. J Urol (2004) 0.80
Presence and enzymatic activity of prostate-specific antigen in archival prostate cancer samples. Oncol Rep (2008) 0.80
Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells. Exp Oncol (2006) 0.79
Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways. Sci Rep (2014) 0.85
Celastrol blocks interleukin-6 gene expression via downregulation of NF-κB in prostate carcinoma cells. PLoS One (2014) 0.81
Growth differentiation factor-15: a p53- and demethylation-upregulating gene represses cell proliferation, invasion, and tumorigenesis in bladder carcinoma cells. Sci Rep (2015) 0.80